Clinical trial readout dates for Exelixis Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 XL092 Colorectal Cancer · NCT05425940 | June 2026 Primary data collected |
| Phase 3 XL092 Non-Clear Cell Renal Cell Carcinoma · NCT05678673 | December 2026 Ongoing |
| Phase 2 Zanzalintinib Meningioma · NCT07428616 | February 2028 Recruiting |
| Phase 2 Carboplatin Squamous Non-Small Cell Lung Cancer (NSCLC) · NCT07845786 | June 2028 Recruiting |
| Phase 2/3 Zanzalintinib Head and Neck Squamous Cell Carcinoma · NCT06082167 | August 2028 Ongoing |
| Phase 2/3 Zanzalintinib Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET) · NCT06943755 | June 2029 Recruiting |
| Phase 3 Zanzalintinib Colorectal Cancer · NCT07750158 | April 2030 Recruiting |
| Phase 3 Cabozantinib Cancer; Renal Cell Carcinoma (RCC) · NCT07620574 | May 2030 Enrolling |
Exelixis Inc. reported $1.52B in cash, cash equivalents and marketable securities at Oct 2, 2026 (10-Q filed 2026-10-29). It reported net income of $218M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-29 |